Frontiers in Synaptic Regeneration: Tazbentetol for Schizophrenia

David Walling, PhD, discussed preliminary findings on tazbentetol, an investigational compound under development by Spinogenix for schizophrenia, Alzheimer disease, and amyotrophic lateral sclerosis.

Walling explained that tazbentetol is hypothesized to work through synaptic regeneration—specifically, restoration of dendritic spine synapses lost in neurodegenerative and neuropsychiatric conditions. He situated this mechanism within the broader landscape of antipsychotic pharmacology, contrasting it with agents that target dopamine and serotonin receptors, as well as the more recently approved muscarinic receptor agent, noting that all prior drugs "focus on specific areas of the brain and blocking something in those areas," whereas tazbentetol may enable neuronal regrowth.

Walling presented findings from a planned interim analysis of an ongoing combination-therapy trial. Despite the small cohort size, he noted reported signals of improvement across multiple domains, including cognition and both positive and negative symptom subscales of the Positive and Negative Syndrome Scale.¹ He emphasized that "not only is this drug potentially having an impact on cognition, but it's also potentially having an impact on the symptom presentation of subjects who enter the study."

Additional features of interest included a rapid onset of action, a potentially durable effect on spine density observed in animal models over several weeks, and a safety and tolerability profile characterized by mild adverse events—headache, somnolence, insomnia, nausea, and fatigue—without findings of particular concern.² Electroencephalography was described as a candidate biomarker, citing a consortium paper which has been submitted to the US Food and Drug Administration.

Walling noted that the full dataset is expected in 2026 and expressed hope that Spinogenix would advance tazbentetol into a larger phase 2 trial, with future study design contingent on effect sizes across symptom and cognitive domains.

Dr Walling is a clinical psychologist and chief clinical officer for psychiatry at CenExcel.

References

1. Walters J. Tazbentetol for schizophrenia shows symptom improvement in phase 2 trial. Psychiatric Times. March 26, 2026. https://www.psychiatrictimes.com/view/tazbentetol-for-schizophrenia-shows-symptom-improvement-in-phase-2-trial

2. Study of SPG302 in adults with schizophrenia. ClinicalTrials.gov. February 6, 2026. Accessed April 24, 2026. https://clinicaltrials.gov/study/NCT06442462?term=spinogenix&rank=2